SBRT plus systemic therapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding targeted radiation therapy (SBRT) to standard systemic therapy helps people with advanced liver cancer live longer compared to systemic therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced liver cancer (BCLC stage C) that has spread to the main liver vein or to other organs.
- You have not had any systemic cancer treatment (like pills or IV therapy) for this current liver cancer.
- Your liver function is good enough (Child-Pugh score 7 or less).
- You are able to take care of yourself and be out of bed for at least part of the day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This early-phase trial tests a treatment plan that combines focused radiation with two medicines—an immunotherapy drug and an anti-angiogenesis drug—to treat hepatocellular carcinoma (liver cancer). It may help shrink tumors or control disease when surgery or ablation can’t be used, and when systemic (whole-body) treatment is needed.
This trial tests a combination of liver-directed radiation therapy, an immunotherapy drug (which helps your immune system fight cancer), and a drug that blocks blood vessel growth to the tumor. It is for people with advanced liver cancer that cannot be treated with surgery.
This trial tests combining an immunotherapy drug (sintilimab) with targeted radiation therapy before surgery to shrink liver tumors and improve the chances of successful removal. It is designed for people with resectable liver cancer who have not yet had systemic treatment.
This trial tests whether a targeted radiation therapy (SBRT) can help people with liver cancer whose disease has only a few new spots growing while on first-line immunotherapy. It aims to see if zapping those spots can control the cancer and delay the need for stronger treatments.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.